Abstract: The present disclosure relates to a pharmaceutical composition containing an inhibitor against the expression or activation of a novel ADP-ribosyl cyclase or a naturally occurring variant thereof as an active ingredient for preventing or treating an ADP-ribosyl cyclase-mediated disease. In addition, the present disclosure relates to a composition for diagnosis of an ADP-ribosyl cyclase-mediated disease, the composition containing an agent for measuring a gene expression level or protein level of the ADP-ribosyl cyclase or a naturally occurring variant thereof. The composition of the present disclosure has the effect of inhibiting calcium increase in kidney cells, which is attributed to angiotensin II-induced ADP-ribosyl cyclase expression or activation, and as such can be advantageously used as a therapeutic agent for an ADP-ribosyl cyclase-mediated disease, particularly a renal disease.

Abstract: When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries.

Abstract: When using a pharmaceutical composition for preventing or treating malignant hyperthermia, containing NAADP antagonists, of the present invention, malignant hyperthermia can be effectively prevented or treated through the inhibition of an oxygen consumption rate abnormal increase, which is associated with a ryanodine receptor (RYR) of skeletal muscles. In addition, the present invention can be used even after the onset of malignant hyperthermia and can inhibit an oxygen consumption rate abnormal increase even at concentrations lower than those of conventional agents for treating malignant hyperthermia, thereby enabling conventional agents for treating malignant hyperthermia to be replaced, and can be stably used, thereby being effectively usable in relevant industries.

Abstract: The present disclosure relates to a composition for regulating prostasome secretion, comprising an intracellular calcium signaling second messenger or a regulator thereof. The techniques to promote and regulate the prostasome secretion according to the present disclosure is mainly characterized by providing techniques for regulating exosome secretion based on the signaling mechanism in prostate cells. In particular, since it can directly regulate the secretion of prostasome that imparts motility to the sperm, it can he used for the verification of sperm motility in the diagnosis or treatment of infertility and can be used for the improvement of fertility and for contraception.

Abstract: The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization.

Abstract: Provided are a method of preparing a zinc oxide nanostructure electrode and a method of preparing a dye-sensitized solar cell using the same. The present invention relates to a use of nicotinic acid adenine dinucleotide phosphate or a derivative thereof for promoting the differentiation of keratinocytes into fibroblasts. The present invention provides a pharmaceutical or cosmetic use of a composition containing NAADP or a derivative thereof for regenerating and improving a skin barrier, or preventing, improving or treating stratum corneum disorders such as psoriasis or atopy, and a use for promoting the differentiation of separated keratinocytes.

Abstract: Provided are a method of preparing a zinc oxide nanostructure electrode and a method of preparing a dye-sensitized solar cell using the same. The present invention relates to a use of nicotinic acid adenine dinucleotide phosphate or a derivative thereof for promoting the differentiation of keratinocytes into fibroblasts. The present invention provides a pharmaceutical or cosmetic use of a composition containing NAADP or a derivative thereof for regenerating and improving a skin barrier, or preventing, improving or treating stratum corneum disorders such as psoriasis or atopy, and a use for promoting the differentiation of separated keratinocytes.

Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.

Abstract: The present invention relates to a pharmaceutical composition for promoting fertilization comprising cyclic ADP-ribose or its derivative, CD38 and to a method of promoting fertilization by promoting the synthesis of cyclic ADP-ribose to increase sperm motility. Also, the present invention relates to a pharmaceutical composition for contraception and a method for inhibiting fertilization, which can inhibit the expression or function of cyclic ADP-ribose to reduce sperm motility, thereby inhibiting fertilization.

Abstract: The administration of nicotinic acid adenine dinucleotide phosphate (NAADP) or a pharmaceutically acceptable salt thereof to a host in need thereof for the treatment of type-2 diabetes has been disclosed.

Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.

Abstract: The present disclosure relates to bisphenyl compounds that are useful for inhibit the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.

Abstract: Nicotinic acid adenine dinucleotide phosphate and a pharmaceutically acceptable derivative thereof are useful for the treatment of type-2 diabetes.

Abstract: The present invention provides the use of L-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes(NIDDM; non-insulin dependent diabetes mellitus). The present invention also provides the pharmaceutical composition containing the chemical L-2-oxothiazolidine-4-carboxylic acid as an active agent for the treatment of type 2 diabetes and the method for the treatment of type 2 diabetes comprising administering to a mammal having the same disease.